Diabetes therapy : research, treatment and education of diabetes and related disordersSep 1, 2026

Combined SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Link to Heart Attacks and Strokes in Type 2 Diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Sep 2, 2026

Abstract

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists may provide cardioprotection in type 2 diabetes mellitus.

Monotherapy with SGLT2 inhibitors or GLP-1 receptor agonists is associated with reduced risk of myocardial infarction and stroke.
Combined use of SGLT2 inhibitors and GLP-1 receptor agonists may enhance cardioprotective effects compared to monotherapy.
The evaluation focuses on the prevention of cardiovascular events specifically in patients with type 2 diabetes mellitus.

Simplified

Full Text

Full text is available at the source.

View Full Text ↗

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

GLP-1 drugs don't build habits — and that gap is costing patients their results

5 days ago7 studies

Semaglutide slowed aging and extended lifespan in older female mice

1 week ago7 studies

GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes

2 weeks ago7 studies

Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes

3 weeks ago7 studies

A once-daily pill beat placebo on weight loss — and it wasn't semaglutide

4 weeks ago7 studies

GLP-1 drugs work even without weight loss — and scientists are finally mapping why

5 weeks ago7 studies

Stop the drug, regain the weight: pooled data puts the average rebound at 7%

6 weeks ago7 studies

The brain region that explains why blocking and activating the same receptor both cause weight loss

7 weeks ago7 studies

GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study

8 weeks ago7 studies

Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

9 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief